Trial Profile
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tigatuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
- 29 Jun 2015 Planned End Date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.